Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Nutt

Showing results (61-70 of 389) with videos related to

Pageof 39
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2003
Brain imaging studies in human addictsMark R C Daglish, David J Nutt
Hospital Medicine (London, England : 1998)|October 3, 2002
Venlafaxine: a new class of antidepressantJulia Hardy, Spilios Argyropoulos, David J Nutt
Psychopharmacology Bulletin|December 20, 2002
Mechanism of action of antidepressantsFrancesc Artigas, David J Nutt, Richard Shelton
Journal of Psychopharmacology (Oxford, England)|April 24, 2012
Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?David R Owen, Rainer Rupprecht, David J Nutt
Journal of Psychopharmacology (Oxford, England)|January 31, 2012
Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?David J Nutt, Anne Lingford-Hughes, Jonathan Chick
History of Psychiatry|February 16, 2017
Concerns regarding conclusions made about LSD-treatments (received 25 October 2016)David Erritzoe, David J Nutt, Robin Carhart-Harris
Frontiers in Psychiatry|October 18, 2014
Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive AttenuationsDaniela A Herzig, David J Nutt, Christine Mohr
The New England Journal of Medicine|August 26, 2021
Psilocybin for Depression. ReplyRobin Carhart-Harris, Allan Blemings, David J Nutt
Expert Review of Pharmacoeconomics & Outcomes Research|February 23, 2024
Using real world evidence to optimize care: the case of medical cannabisAnne Katrin Schlag, David J Nutt, Michael Lynskey
Convulsive Therapy|January 1, 1989
Neuropharmacological Aspects of ECT: In Search of the Primary Mechanism of ActionDavid J. Nutt, Christoph H. Gleiter, Paul Glue
Pageof 39

Showing results (61-70 of 389) with videos related to

Sort By:
Pageof 39
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2003
Brain imaging studies in human addictsMark R C Daglish, David J Nutt
Hospital Medicine (London, England : 1998)|October 3, 2002
Venlafaxine: a new class of antidepressantJulia Hardy, Spilios Argyropoulos, David J Nutt
Psychopharmacology Bulletin|December 20, 2002
Mechanism of action of antidepressantsFrancesc Artigas, David J Nutt, Richard Shelton
Journal of Psychopharmacology (Oxford, England)|April 24, 2012
Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?David R Owen, Rainer Rupprecht, David J Nutt
Journal of Psychopharmacology (Oxford, England)|January 31, 2012
Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?David J Nutt, Anne Lingford-Hughes, Jonathan Chick
History of Psychiatry|February 16, 2017
Concerns regarding conclusions made about LSD-treatments (received 25 October 2016)David Erritzoe, David J Nutt, Robin Carhart-Harris
Frontiers in Psychiatry|October 18, 2014
Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive AttenuationsDaniela A Herzig, David J Nutt, Christine Mohr
The New England Journal of Medicine|August 26, 2021
Psilocybin for Depression. ReplyRobin Carhart-Harris, Allan Blemings, David J Nutt
Expert Review of Pharmacoeconomics & Outcomes Research|February 23, 2024
Using real world evidence to optimize care: the case of medical cannabisAnne Katrin Schlag, David J Nutt, Michael Lynskey
Convulsive Therapy|January 1, 1989
Neuropharmacological Aspects of ECT: In Search of the Primary Mechanism of ActionDavid J. Nutt, Christoph H. Gleiter, Paul Glue
Pageof 39